Advertisement
Screener

Coherus Oncology, Inc. (CHRS) Long-term Debt, Gross

2.8 / 5 stars · 68/120 Roast Me

Coherus Oncology, Inc. Long-term Debt, Gross

Coherus Oncology, Inc. (CHRS) had Long-term Debt, Gross of $133.60 million as of 2019-09-30, per its 10-Q filed 2019-11-08.

Discontinued › Notes › Debt › Debt Instruments

us-gaap:DebtInstrumentCarryingAmount · last filed 2019-11-08

  • 2019-09-30: Long-term Debt, Gross $133.60M.
  • 2019-06-30: Long-term Debt, Gross $133.60M.
  • 2019-03-31: Long-term Debt, Gross $133.60M.
Period endLong-term Debt, Gross
2019-09-30$133.60M
10-Q · filed 2019-11-08
2019-06-30$133.60M
10-Q · filed 2019-08-05
2019-03-31$133.60M
10-Q · filed 2019-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alpha Cognition Inc. (ACOG)$0.185B-6.77
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Alector, Inc. (ALEC)United States$0.213B-1.90
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37